A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä
Respiratory Syncytial Virus–Associated Hospitalization in Adults With Comorbidities in 2 European Countries: A Modeling Study
Tekijät: Osei-Yeboah R., Johannesen C.K., Egeskov-Cavling A.M., Chen J., Lehtonen T., Fornes A.U., Paget J., Fischer T.K., Wang X., Nair H., Campbell H.; on behalf of the PROMISE Investigators
Kustantaja: Oxford University Press
Julkaisuvuosi: 2024
Journal: Journal of Infectious Diseases
Tietokannassa oleva lehden nimi: Journal of Infectious Diseases
Vuosikerta: 229
Numero: Suppl. 1
Aloitussivu: S70
Lopetussivu: S77
DOI: https://doi.org/10.1093/infdis/jiad510
Verkko-osoite: https://doi.org/10.1093/infdis/jiad510
Background: Individuals with comorbidities are at increased risk of severe respiratory syncytial virus (RSV) infection. We estimated RSV-associated respiratory hospitalization among adults aged ≥45 years with comorbidities in Denmark and Scotland.
Methods: By analyzing national hospital and virologic data, we estimated annual RSV-associated hospitalizations by 7 selected comorbidities and ages between 2010 and 2018. We estimated rate ratios of RSV-associated hospitalization for adults with comorbidity than the overall population.
Results: In Denmark, annual RSV-associated hospitalization rates per 1000 adults ranged from 3.1 for asthma to 19.4 for chronic kidney disease (CKD). In Scotland, rates ranged from 2.4 for chronic liver disease to 9.0 for chronic obstructive pulmonary disease (COPD). In both countries, we found a 2- to 4-fold increased risk of RSV hospitalization for adults with COPD, ischemic heart disease, stroke, and diabetes; a 1.5- to 3-fold increased risk for asthma; and a 3- to 7-fold increased risk for CKD. RSV hospitalization rates among adults aged 45 to 64 years with COPD, asthma, ischemic heart disease, or CKD were higher than the overall population.
Conclusions: This study provides important evidence for identifying risk groups and assisting health authorities in RSV vaccination policy making.
Julkaisussa olevat rahoitustiedot:
101034339/Innovative Medicines Initiative 2 Joint Undertaking NMUR20210009/Nanjing Medical University Talents Start-up Grants European Union's Horizon 2020 Research and Innovation Programme